Table 3.

The association between inositol intake and lipid profiles based on subgroup analysis

Variables		Number of SMD included	Subgroups	Pooled OR (random effect)	95% CI	I2 (%)	Overall I2 (%)
Triglycerides	Type of disease	5	PCOS	−0.74	−1.66, 0.18	91.7	93.2
		7	Non-PCOS	−1.58	−2.32, −0.85	92.1
	Dosage of inositol (mg/day)	6	≥2000	−0.83	−1.49, − 0.18	83.4
		6	<2000	−1.69	−2.69, −0.68	96.2
	Duration of study (week)	5	≥14	−1.64	−2.94, −0.34	93.4
		7	<14	−0.99	−1.67, − 0.32	93.1
	Type of intervention	4	DCI	−0.32	−0.66, 0.01	0.0
		6	MI	−1.15	−1.91, −0.39	94.0
		2	MI + DCI	−3.37	−6.00, −0.75	94.2
Total cholesterol	Type of disease	5	PCOS	−0.86	−1.72, − 0.02	90.3	93.6
		6	Non-PCOS	−1.49	−2.51, −0.46	95.5
	Dosage of inositol (mg/day)	5	≥2000	−0.82	−1.91, 0.28	92.2
		6	<2000	−1.51	−2.38, −0.63	95.2
	Duration of study (week)	5	≥14	−1.77	−3.31, −0.22	95.0
		6	<14	−0.74	−1.33, − 0.15	90.5
	Type of intervention	4	DCI	−0.22	−0.62, 0.18	26.2
		5	MI	−0.91	−1.59, − 0.24	91.9
		2	MI + DCI	−3.76	−5.68, −1.85	88.2
LDL-cholesterol	Type of disease	3	PCOS	−0.60	−1.51, 0.31	86.1	92.2
		2	Non-PCOS	−1.84	−3.41, 0.26	93.1
	Dosage of inositol (mg/day)	3	≥2000	−0.86	−2.27, 0.54	93.2
		2	<2000	−2.00	−3.98, −0.03	94.8
	Duration of study (week)	4	≥14	−1.39	−2.78, −0.01	94.0
		1	<14	−1.03	− 1.37, −0.70	0.0
	Type of intervention	2	DCI	−0.15	− 0.61, 0.30	0.0
		1	MI	−1.03	−1.37, −0.70	–
		2	MI + DCI	−2.59	−3.39, −1.81	56.7
HDL-cholesterol	Type of disease	3	PCOS	0.38	0.12, 0.64	2.4	89.4
		7	Non-PCOS	0.14	−0.56, 0.84	92.7
	Dosage of inositol (mg/day)	5	≥2000	0.01	−0.59, 0.62	81.1
		5	<2000	0.37	−0.31, 1.04	92.2
	Duration of study (week)	4	≥14	−0.61	−1.35, 0.14	83.5
		6	<14	0.68	0.42, 0.95	55.1
	Type of intervention	3	DCI	0.19	−0.17, 0.55	0.0
		5	MI	0.72	0.42, 1.02	62.0
		2	MI + DCI	−1.22	−1.73, −0.71	36.2

MI myo-inositol, DCI D-chiro-Inositol, PCOS polycystic ovary syndrome